Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05891197 · ClinicalTrials.gov registry record
A Biomarker Screening Protocol for Participants With Solid Tumors
A clinical trial, sponsored by Lyell Immunopharma.
- Terminated
- Registry status
- 10
- Enrollment target
NCT05891197: Clinical Trial study, sponsored by Lyell Immunopharma.
NCT05891197 is a clinical trial that was terminated before completion, run by Lyell Immunopharma. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05891197 was terminated before completion, sponsored by Lyell Immunopharma.
- TERMINATED
- Registry status
- 10 participants
- Enrollment target
Study Summary
Biomarker Screening Protocol for Preliminary Eligibility Determination for Adoptive T-cell Therapy Trials:This is a decentralized, multi-site, US-based biomarker screening study to identify participants who have specific disease indications and tumor expression of target(s) of interest that may inform eligibility for active and future Lyell clinical trials. No investigational treatments will be administered in this non-interventional screening study. Only previously obtained archival tumor tissue will be allowed on this study for biomarker analysis. Fresh tumor biopsies are not permitted on this study. The study will be conducted virtually and participants will utilize telehealth and e-consent modules. If participants tumors express the biomarkers of interest they can be referred to open and enrolling clinical trials. Participation on the screening study does not guarantee enrollment or treatment on an interventional clinical trial.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-05-19 |
| Est. Completion | 2025-02-05 |
Why NCT05891197 stopped before completion
NCT05891197 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT05891197 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05891197 about?
NCT05891197 is a clinical study titled "A Biomarker Screening Protocol for Participants With Solid Tumors". Biomarker Screening Protocol for Preliminary Eligibility Determination for Adoptive T-cell Therapy Trials:This is a decentralized, multi-site, US-based biomarker screening study to identify participants who have specific disease indications and tumor expression of target(s) of interest that may info...
What is the current status of trial NCT05891197?
This trial is currently terminated. The enrollment target is 10 participants. The study started on 2023-05-19. Estimated completion is 2025-02-05.
Who is sponsoring clinical trial NCT05891197?
This trial is sponsored by Lyell Immunopharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI